Neonatal respiratory distress syndrome (RDS) remains a leading cause of morbidity and mortality in preterm infants. This condition stems primarily from an insufficiency in pulmonary surfactant, a ...
Please provide your email address to receive an email when new articles are posted on . Minimally invasive surfactant therapy did not lower mortality among preterm infants with respiratory distress ...
The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant ...
LA JOLLA, CA - Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin® (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant ...
HealthDay News — The FDA has approved Surfaxin (lucinactant) to prevent respiratory distress syndrome (RDS) in premature infants. Premature infants born before 37 weeks’ gestation often cannot produce ...
A nine-month-old infant with severe respiratory complications was airlifted from Raipur to Hyderabad and treated at KIMS ...
Holly Jordan's premature son survived — thanks to medical advances after Patrick Kennedy's death from Infant Respiratory Distress Syndrome decades earlier Holly Jordan, who works in business ...
Please provide your email address to receive an email when new articles are posted on . Researchers observed high lysolipid levels in those with acute respiratory distress syndrome (ARDS), which may ...
Researchers may have discovered a mechanical explanation for instability observed in the lungs in cases of acute respiratory distress syndrome (ARDS), particularly in the aftermath of respiratory ...
The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results